COMMUNIQUÉS West-GlobeNewswire

RAMSAY GENERALE DE SANTE : AMENDEMENT ET EXTENSION DE LA CONVENTION DE CREDIT SENIOR
11/08/2017
Paris, le 11 août 2017 « Communiqué de Presse » Ramsay Générale de Santé Amendement et extension de la convention de crédit senior Ramsay Générale de Santé, leader de l'hospitalisation privée en France a finalisé avec [...]
RAMSAY GENERALE DE SANTE : AMEND AND EXTEND OF ITS SENIOR FACILITIES AGREEMENT
11/08/2017
Paris, 11th August 2017 « Press Release » Ramsay Générale de Santé Amend and Extend of its Senior Facilities Agreement Ramsay Générale de Santé, the leading private hospital group in France, on 11 August 2017 [...]
ProMIS Neurosciences Announces Second Quarter 2017 Results
11/08/2017
TORONTO and CAMBRIDGE, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (" ProMIS " or the " Company "), a company focused on the discovery and development of precision treatments for [...]
PCI Biotech: First patient dosed in the fimaCHEM Phase I extension study
11/08/2017
Oslo, 11 August 2017 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the first patient has been dosed in the fima Chem Phase I extension study with the objective to evaluate [...]
Notice of Nexstim Plc's Half-Yearly Report H1 2017
11/08/2017
Company announcement, Helsinki, 11 August 2017 at 9:00 am Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]
ESPERITE (ESP): L1 Capital confirms its investment in Esperite and announces new funding for up to EUR 0.6 million before August 31, 2017
11/08/2017
Zutphen, The Netherlands, 11 August 2017 As of today, EUR 2,090,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 250,000 of warrants out of a total potential [...]
ABLYNX ANNOUNCES WARRANT EXERCISE
11/08/2017
REGULATED INFORMATION GHENT, Belgium, 11 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an [...]
EDAP-TMS to Announce Second Quarter 2017 Financial Results on Wednesday, August 23, 2017
10/08/2017
PRESS RELEASE Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com Investors: Rich Cockrell CG CAPITAL 877.889.1972 rich@cg.capital EDAP-TMS to Announce Second [...]
Reviewed Financial Statement's announcement for the period 30 June 2017
10/08/2017
EASTPHARMA LTD. London, 10 August 2017 - EastPharma (EAST LI) announces that it is releasing its reviewed financial statements for the period 30 June 2017. Management comment on the financial performance of EastPharma [...]
Ossur Hf : Insider Trading
10/08/2017
Announcement Össur hf. No.56/2017 Reykjavík, 10 August 2017 Auðkenni útgefanda/Trade ticker: OSSR Nafn útgefanda/Issuer: Össur hf. Dagsetning tilkynningar/Date of announcement: 10 August 2017 Nafn fruminnherja/Name [...]
Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2017
10/08/2017
Bagsværd, Denmark, 10 August 2017 - This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article [...]
Zealand Pharma A/S publishes prospectus
10/08/2017
Zealand Pharma A/S publishes prospectus. Zealand Pharma - Danish Prospectus - 10 August 2017 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The [...]
Zealand Pharma A/S publishes a prospectus regarding listing of 4,375,000 new shares on Nasdaq Copenhagen as part of its issue of American Depositary Shares listed on the Nasdaq in the US
10/08/2017
Zealand Pharma A/S will today publish a prospectus approved by the Danish Financial Supervisory Authority for the admission to trading and official listing of 4,375,000 new shares on Nasdaq Copenhagen under the symbol " [...]
RedHill Biopharma Provides 2017 Semi-Annual Business Update
10/08/2017
RedHill's U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill's late clinical-stage GI products, if approved, and for the acquisition [...]
Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
10/08/2017
Phase 3 results from AM-111 HEALOS trial expected in fourth quarter 2017 Phase 3 results from Keyzilen ® TACTT3 trial expected in first quarter 2018 Conference call set for 8 am EDT (2 pm CEST) today Zug, Switzerland, [...]
Présentation de Merus à la Wedbush PacGrow Healthcare Conference 2017
10/08/2017
UTRECHT, Pays-Bas, le 10 août 2017 (GLOBE NEWSWIRE) - Merus N.V. (NASDAQ : MRUS), une entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps bispécifiques (Biclonics [...]
Active Biotech AB - Interim report January - June 2017
10/08/2017
Second quarter in brief In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma The primary clinical endpoint from the Phase III trial of [...]
Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel
10/08/2017
Press Release 10 August 2017 Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel Immunicum AB (publ; First North Premier: IMMU.ST), a [...]
Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs
10/08/2017
Completed license agreement with Pfizer for Cresemba in Europe (excluding Nordics), Russia, Turkey and Israel; CHF 70 million upfront payment and up to USD 427 million in milestones 56 percent increase in total revenue [...]

Pages